학술논문
Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project
Document Type
article
Author
Stefano Porru; Maria Grazia Lourdes Monaco; Gianluca Spiteri; Angela Carta; Gulser Caliskan; Concepción Violán; Pere Torán-Monserrat; Luigi Vimercati; Silvio Tafuri; Paolo Boffetta; Francesco Saverio Violante; Emma Sala; Emanuele Sansone; Fabriziomaria Gobba; Loretta Casolari; Andreas Wieser; Christian Janke; Adonina Tardon; Marta Maria Rodriguez-Suarez; Filippo Liviero; Maria Luisa Scapellato; Marco dell’Omo; Nicola Murgia; Dana Mates; Violeta Claudia Calota; Jozef Strhársky; Mariana Mrázová; Enrico Pira; Alessandro Godono; Greta Camilla Magnano; Corrado Negro; Giuseppe Verlato; Orchestra WP5 Working Group
Source
Journal of Epidemiology and Global Health, Vol 13, Iss 3, Pp 577-588 (2023)
Subject
Language
English
ISSN
2210-6014
Abstract
Abstract Background SARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue. Methods Multicentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose. Results 13,093 (20.6%) BI were observed. The cumulative incidence of BI was higher in women and in HW aged 130 days. Conclusions The risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics.